Exploring the companies and themes that make up this emerging and exciting new sector
The Future of Psychedelic Medicine: Two DIFFERENT Treatment Models
Spiritual journey or clinical therapy? What does the future of psychedelic medicine look like?
Mindset Pharma Identifies New Pharmacological Insights of First Generation Psychedelics Through its COPE Program with InterVivo Solutions
Mindset announces new insights in research on psychedelics molecules via its COPE initiative.
Novamind Advances Clinical Pilot for Frontline KAP
Novamind announces a "clinical pilot" aimed at bringing ketamine-assisted therapy to treat the mental health disorders of frontline healthcare workers.
Hawaii Senators Approve Psilocybin Task Force Bill In Committee, With Decriminalization Measures Still Pending
A Hawaii Senate committee on Friday approved a bill to set up a state working group to study the therapeutic benefits of psilocybin mushrooms.
Psychedelic Medicine For PTSD: The Key To U.S. Legal Reforms
There are many valid reasons to push forward with legal reforms to advance psychedelic medicine. In the U.S., however, it is the treatment of PTSD that is bringing Republicans and Democrats together.
Cybin Inc. Reports Third Quarter Financial Results and Recent Business Highlights
Cybin announces its Q3 results, supported by a conference call. Cash as of Decemeber 31, 2021 of CAD$63.6 million.
Cybin Announces Grant of U.S. Patent Covering its Proprietary Compound CYB004 (Deuterated DMT) for the Treatment of Anxiety Disorders
Cybin announces receiving a composition of matter patent for its DMT-derived compound, CYB004 from the the USPTO.
5 Superb Values In Psychedelic Stocks, 5 Different Reasons To Buy
Cheap stocks. Many reasons to invest. We selected five different companies who illustrated these value propositions.
Elemental Advisors Launches PSYK ETF Focused on the Medical Psychedelics Industry
A new U.S.-based psychedelics ETF will begin trading on the NYSE, symbol "PSYK".
Optimi Health Dealer’s License Granted by Health Canada
Optimi Health announces receiving its Dealer's License from Health Canada, allowing the possession, production and sale of psilocybin.
Novamind Hosts Clinical Trial to Advance Ketamine Therapy for End-of-Life Patients
Novamind will host a Phase II clinical trial by the Ketamine Research Foundation for ketamine therapy for the terminally ill.